Technology ID

Cyclopentane-modified FIT-PNAs as Highly Emissive and Selective RNA/DNA Sensors for Use in Clinical Diagnostics

Lead Inventor
Yavin, Eylon (Yissum Research Development Company)
Appella, Daniel (NIDDK)
Zheng, Hongchao (NIDDK)
Software / Apps
Research Materials
Non-Medical Devices
Medical Devices
Lead IC
This technology includes Cyclopentane-modified Peptide Nucleic Acids (cp-PNAs) which can be combined with (forced-intercalation) FIT-PNAs to create highly sensitive probes that detect the presence of complementary RNA sequences. We have studied the beneficial effects of incorporating cyclopentane groups into the backbone of PNAs, which leads to proper preorganization of the PNA backbone into the conformations needed to bind complementary RNA sequences. The cp-PNAs typically have improved thermodynamic stability for binding to complementary nucleic acids compared to unmodified PNAs. FIT-PNAs have a fluorescent group attached to one position in a PNA sequence so that the fluorescent group replaces one nucleobase in the sequence. When a FIT-PNA binds to complementary RNA, the fluorescence increases due to steric hindrance in the bound PNA. By combining cp-PNA and FIT-PNA strategies, more sensitive RNA detection is achieved. The PNAs that contain both cyclopentane groups and also a FIT group are called cpFIT-PNAs.
Commercial Applications
The new cpFIT-PNAs should be useful to detect biologically relevant RNA sequences associated with different disease states, such as cancer or viral infections or bacterial infections, and can be used when analyzing fresh human tissues or human fluid samples in clinical settings.

Competitive Advantages
Potentially applicable to the development of clinical diagnostics.
Licensing Contact: